In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located ...at 7q36.1, is frequently targeted in MDS. Analysis of EZH2 deletions, missense and frameshift mutations strongly suggests that EZH2 is a tumor suppressor. As EZH2 functions as a histone methyltransferase, abnormal histone modification may contribute to epigenetic deregulation in MDS.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
Myelodysplastic syndromes (MDS) represent a heterogeneous group of neoplastic hematopoietic disorders. Several recurrent chromosomal aberrations have been associated with MDS, but the genes affected ...have remained largely unknown. To identify relevant genetic lesions involved in the pathogenesis of MDS, we conducted SNP array-based genomic profiling and genomic sequencing in 102 individuals with MDS and identified acquired deletions and missense and nonsense mutations in the TET2 gene in 26% of these individuals. Using allele-specific assays, we detected TET2 mutations in most of the bone marrow cells (median 96%). In addition, the mutations were encountered in various lineages of differentiation including CD34+ progenitor cells, suggesting that TET2 mutations occur early during disease evolution. In healthy tissues, TET2 expression was shown to be elevated in hematopoietic cells with highest expression in granulocytes, in line with a function in myelopoiesis. We conclude that TET2 is the most frequently mutated gene in MDS known so far.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
Patients with acute myeloid leukemia (AML) frequently harbor mutations in genes involved in the DNA (hydroxy)methylation pathway (DNMT3A, TET2, IDH1, and IDH2). In this study, we measured ...5-hydroxymethylcytosine (5hmC) levels in 206 clinically and molecularly well-characterized younger adult AML patients (≤60 years) included in the European Organization for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC/GIMEMA) AML-12 06991 clinical trial and correlated the 5hmC levels with mutational status and overall survival (OS). In healthy control cells, 5hmC levels were confined to a narrow range (1.5-fold difference), whereas in AML cells, a much wider range was detected (15-fold difference). We identified 3 5hmC subpopulations in our patient cohort (low, intermediate, and high). The low 5hmC group consisted almost entirely of patients with TET2 or IDH mutations. As expected, TET2 and IDH mutated patients had significantly lower levels of 5hmC compared with patients without mutated TET2 and IDH1/2 (both P < .001). Interestingly, high 5hmC levels correlated with inferior OS (high vs intermediate 5hmC: P = .047, hazard ratio HR = 1.81). Multivariate analysis revealed that high 5hmC is an independent poor prognostic indicator for OS (high vs intermediate 5hmC: P = .01, HR = 2.10). This trial was registered at www.clinicaltrials.gov as NCT00004128.
•5hmC levels vary considerably in patients with AML.•High levels of 5hmC independently correlate with inferior overall survival in AML.
We assessed the prognostic impact of
TET2
mutations and mRNA expression in a prospective cohort of 357 adult AML patients < 60 years of age enrolled in the European Organization For Research and ...Treatment of Cancer (EORTC)/Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) AML-12 06991 clinical trial. In addition the co-occurrence with other genetic defects and the functional consequences of
TET2
mutations were investigated.
TET2
mutations occurred in 7.6 % of the patients and were an independent marker of poor prognosis (
p
= 0.024).
TET2
and
IDH1
/
2
mutations strongly associated with aberrations in the DNA methyltransferase
DNMT3A
. Functional studies confirmed previous work that neither nonsense truncations, nor missense TET2 mutations, induced 5-hydroxymethylcytosine formation. In addition, we now show that mutant
TET2
forms did not act in a dominant negative manner when co-expressed with the wild-type protein. Finally, as loss-of-function
TET2
mutations predicted poor outcome, we questioned whether low
TET2
mRNA expression in cases of AML without
TET2
mutations would affect overall survival. Notably, also AML patients with low
TET2
mRNA expression levels showed inferior overall survival.
Patients with acute myeloid leukemia (AML) frequently harbor mutations in genes involved in the DNA (hydroxy)methylation pathway (DNMT3A, TET2, IDH1, and IDH2). In addition, changes in DNA ...methylation have been implicated in the pathogenesis of AML. Recently it was discovered that TET proteins are able to convert 5-methylcytosine into 5-hydroxymethylcytosine (5hmC), which is an important intermediate in the demethylation pathway. In this study, we measured 5-hydroxymethylcytosine levels in AML patients, and correlated these with mutational status and overall survival (OS).
Samples from 206 clinically and molecularly well-characterized younger adult AML patients (≤60 years), included in the EORTC/GIMEMA AML-12 06991 clinical trial, were analyzed for mutations in DNMT3A, TET2, IDH1 and IDH2. 5-hydroxymethylcytosine levels were measured using HPLC-MS/MS.
In healthy control cells, 5hmC levels were confined to a narrow range (1.5 fold difference), whereas in AML cells, a much wider range was detected (15 fold difference). In remission, 5hmC values were normalized to levels comparable to healthy bone marrow and peripheral blood, indicating that the aberrant 5hmC levels at diagnosis are intrinsic to the leukemic cells. Patients with mutations in TET2 and patients with mutations in IDH1/2 had significantly lower levels of 5hmC compared to patients without mutated TET2 and IDH1/2 (both P<.001), whereas mutations in DNMT3A did not influence 5hmC levels. Patients with bi-allelic TET2 inactivation displayed lower 5hmC levels than patients with one affected allele (P=.003). Among the patients that did not harbor TET2 or IDH mutations, still a wide variation in 5hmC levels was observed, and importantly, both low and very high 5hmC levels correlated with inferior OS (P=.02, HR=1.80 and P=.04, HR=1.97, respectively). Multivariate analysis revealed that abnormal levels of 5hmC were independent prognostic indicators for OS. The difference in OS could not be explained by an initial inferior response to therapy, however, the relapse rate was considerably higher in patients with low and very high 5hmC levels compared to patients with intermediate 5hmC.
Both low and very high levels of 5hmC are markers of poor prognosis in AML, lending further support for testing therapies targeting the DNA hydroxymethylation pathway.
No relevant conflicts of interest to declare.
The inv(16) chromosomal aberration is found in 10% of the cases with AML. The resultant CBFB-MYH11 fusion gene that plays a key-role in the leukemia development, but for full transformation, ...additional genetic hits are necessary. We report that the MYH11 gene overlaps with the NDE1 gene. At their 3 prime ends the genes overlap at the genomic, transcript as well as coding level and as a consequence, the inv(16) disrupts NDE1 in addition to CBFB and MYH11 in 90% of CBFB-MYH11 positive cases. To determine the relevance of Nde1 function in hematopoiesis leukemia development, hematopoiesis was studied in Nde1-/− and Nde1+/− mutant mice. A significant percentage of the Nde1 null mutant mice developed a myeloproliferative (MPD) phenotype at 6–12 months of age. This phenotype was observed in 6 out of 15 (40%) Nde1−/− mice, 2 out of 15 (13%) Nde1+/− mice and none of 4 wild type mice. All mice with the MPD phenotype exhibited a profound splenomegaly with spleen sizes ranging from 5 to 20-fold larger than normal wild type controls. Histopathological analysis demonstrated hypercellular bone marrow, effacement of normal splenic architecture with expansion of a myeloid cells, and infiltration of proliferating myeloid cells in various organs . A 10-fold increase in Gr1+/Mac1+ double positive mature myeloid cells in the spleen was confirmed by flow-cytometric analysis. Peripheral blood analyses showed that the white blood cell counts were slightly elevated in Nde1 mutant mice that had not yet developed a MPD phenotype compared to wild type mice. A somewhat higher white blood cell count was observed in Nde1 mutant mice with MPD phenotype. In the Nde1 mutant mice with or without splenomegaly we did not observe an increase in the number of B- and T-cells as measured by flowcytometer using various lymphoid cell surface markers. Based on these data we conclude that loss of Nde1 function and Nde1 haploinsufficiency results in the onset of a MPD phenotype. Earlier studies showed that Nde1 is a centrosomal protein. To test whether Nde1 is involved in spindle pole formation and chromosome segregation, we analyzed the mitotic behaviour of mouse embryo fibroblasts (MEFs). From passage 3 to passage 10, aneuploid metaphases increased much more rapidly in Nde1−/− MEFs than in the wild type controls. In addition, a broader spectrum of abnormal chromosome numbers was seen in Nde1−/− MEFs. Thus, Nde1 deficiency results in chromosomal instability. To study whether the numerical chromosome abnormalities were associated with aberrant spindle formation we stained Nde1−/− MEFs with a monoclonal antibody against tubulin. Multipolar spindles and misassembled spindles were more frequently observed in Nde1−/− MEFs compared to wild type cells. We conclude that the abnormal chromosomal segregation of Nde1−/− MEFs is associated with defective mitotic spindle structure. Since Nde1 is disrupted in the majority of inv(16) positive AML patients and the disruption in mice resulted in genetic instability and the onset of myeloproliferative disease, we suggest that the disruption of Nde1 in inv(16)+ AML may serve as additional genetic defect that contributes to leukemogenesis.
